

Michael Freundlich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/779704/publications.pdf>

Version: 2024-02-01

44
papers

1,401
citations

361413

20
h-index

330143

37
g-index

54
all docs

54
docs citations

54
times ranked

1787
citing authors

#	ARTICLE	IF	CITATIONS
1	The intersection of mineralocorticoid receptor activation and the FGF23-Klotho cascade: a duopoly that promotes renal and cardiovascular injury. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 211-221.	0.7	9
2	Fibroblast growth factor 23-Klotho and hypertension: experimental and clinical mechanisms. <i>Pediatric Nephrology</i> , 2021, 36, 3007-3022.	1.7	23
3	Educational review: role of the pediatric nephrologists in the work-up and management of kidney stones. <i>Pediatric Nephrology</i> , 2020, 35, 383-397.	1.7	21
4	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. <i>Kidney International Reports</i> , 2020, 5, 1679-1689.	0.8	17
5	Soluble Klotho, a biomarker and therapeutic strategy to reduce bronchopulmonary dysplasia and pulmonary hypertension in preterm infants. <i>Scientific Reports</i> , 2020, 10, 12368.	3.3	22
6	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. <i>Kidney International Reports</i> , 2020, 5, 860-871.	0.8	2
7	Effects of Klotho supplementation on hyperoxia-induced renal injury in a rodent model of postnatal nephrogenesis. <i>Pediatric Research</i> , 2020, 88, 565-570.	2.3	11
8	Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. <i>Kidney International</i> , 2020, 97, 1260-1274.	5.2	31
9	Abdominal Pain in a Patient with Asymmetry. <i>Kidney360</i> , 2020, 1, 314-315.	2.1	0
10	Fibroblast growth factor 23 and tubular sodium handling in young patients with incipient chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2019, 13, 389-396.	2.9	3
11	Health-related quality of life in glomerular disease. <i>Kidney International</i> , 2019, 95, 1209-1224.	5.2	38
12	Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease. <i>Pediatric Nephrology</i> , 2019, 34, 129-135.	1.7	9
13	Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies. <i>American Journal of Hypertension</i> , 2019, 32, 34-44.	2.0	24
14	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. <i>Kidney International Reports</i> , 2018, 3, 1373-1384.	0.8	39
15	Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients. <i>Pediatric Nephrology</i> , 2017, 32, 1103-1108.	1.7	6
16	Chronic kidney disease and cardiac morbidity - What are the possible links?. <i>Progress in Pediatric Cardiology</i> , 2016, 41, 89-95.	0.4	11
17	Fibroblast growth factor-23 and renin-angiotensin system levels in vitamin-D-dependent rickets type I. <i>Pediatric Nephrology</i> , 2016, 31, 1189-1193.	1.7	7
18	Forty-four-hour interdialytic ambulatory blood pressure monitoring and cardiovascular risk in pediatric hemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 33-39.	2.9	5

#	ARTICLE	IF	CITATIONS
19	Abnormalities in renal tubular phosphate handling in children with sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2014, 61, 2267-2270.	1.5	16
20	Longitudinal FGF23 and Klotho axis characterization in children treated with chronic peritoneal dialysis. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 457-463.	2.9	20
21	Paricalcitol Downregulates Myocardial Renin-Angiotensin and Fibroblast Growth Factor Expression and Attenuates Cardiac Hypertrophy in Uremic Rats. <i>American Journal of Hypertension</i> , 2014, 27, 720-726.	2.0	42
22	Capillary rarefaction: an early marker of microvascular disease in young hemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 569-574.	2.9	26
23	Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies. <i>Future Cardiology</i> , 2013, 9, 817-848.	1.2	78
24	Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. <i>Pediatric Nephrology</i> , 2012, 27, 2129-2136.	1.7	55
25	Long-term risk of chronic kidney disease in unilateral multicystic dysplastic kidney. <i>Pediatric Nephrology</i> , 2011, 26, 597-603.	1.7	69
26	Three Decades of Progress in Treating Childhood-Onset Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2192-2199.	4.5	59
27	Two decades of pediatric kidney transplantation in a multi-ethnic cohort. <i>Pediatric Transplantation</i> , 2010, 14, 667-674.	1.0	14
28	Twenty-five Years of Infant Dialysis: A Single Center Experience. <i>Journal of Pediatrics</i> , 2009, 155, 111-117.	1.8	67
29	Obesity and preterm birth: additive risks in the progression of kidney disease in children. <i>Pediatric Nephrology</i> , 2009, 24, 1363-1370.	1.7	82
30	Vitamin D Insufficiency and Deficiency in Children with Early Chronic Kidney Disease. <i>Journal of Pediatrics</i> , 2009, 154, 906-911.e1.	1.8	52
31	Response to Paricalcitol and renin-angiotensin components in remnant kidneys™. <i>Kidney International</i> , 2009, 75, 340.	5.2	0
32	Bisphosphonates in children with hypercalciuria and reduced bone mineral density. <i>Pediatric Nephrology</i> , 2008, 23, 2215-2220.	1.7	23
33	Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. <i>Kidney International</i> , 2008, 74, 1394-1402.	5.2	230
34	Bone mineral content and mineral metabolism during cyclosporine treatment of nephrotic syndrome. <i>Journal of Pediatrics</i> , 2006, 149, 383-389.	1.8	12
35	A novel epithelial sodium channel γ -subunit mutation associated with hypertensive Liddle syndrome. <i>Pediatric Nephrology</i> , 2005, 20, 512-515.	1.7	26
36	Increased Osteoblastic Activity and Expression of Receptor Activator of NF- κ B Ligand in Nonuremic Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2198-2204.	6.1	12

#	ARTICLE	IF	CITATIONS
37	Bone histology in steroid-treated children with non-azotemic nephrotic syndrome. <i>Pediatric Nephrology</i> , 2004, 19, 400-407.	1.7	35
38	Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1396-1401.	0.7	55
39	More on aluminum toxic effects in children with uremia. <i>Journal of Pediatrics</i> , 1990, 117, 1007-1008.	1.8	3
40	Less Commonly Recognized Features of Childhood Nephrotic Syndrome. <i>Pediatric Clinics of North America</i> , 1987, 34, 591-607.	1.8	18
41	Treatment of aluminum toxicity in infantile uremia with deferoxamine. <i>Journal of Pediatrics</i> , 1986, 109, 140-143.	1.8	7
42	Calcium and vitamin D metabolism in children with nephrotic syndrome. <i>Journal of Pediatrics</i> , 1986, 108, 383-387.	1.8	53
43	Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome. <i>Journal of Pediatrics</i> , 1984, 104, 61-64.	1.8	50
44	Management of chloramphenicol intoxication in infancy by charcoal hemoperfusion. <i>Journal of Pediatrics</i> , 1983, 103, 485-487.	1.8	11